Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles from Lebanon
Based on 13 articles published since 2008

These are the 13 published articles about Psoriasis that originated from Lebanon during 2008-2019.
+ Citations + Abstracts
1 Review The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. 2018

Marchesoni, Antonio / De Marco, Gabriele / Merashli, Mira / McKenna, Frank / Tinazzi, Ilaria / Marzo-Ortega, Helena / McGonagle, Dennis G. ·UOC Day Hospital of Rheumatology, ASST Gaetano Pini-CTO Hospital, Milano, Italy. · NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust. · Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK. · Division of Rheumatology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. · Rheumatology Department, Central Manchester University Hospitals NHS Trust, Trafford General Hospital, Manchester, UK. · Unit of Rheumatology, Sacro Cuore Don Calabria Hospital, Negrar, Italy. ·Rheumatology (Oxford) · Pubmed #28387854.

ABSTRACT: The recognition of the primacy of enthesitis in animal models of spondyloarthritis and the prevalence of clinically occult enthesopathy in psoriatic subjects and of persistent joint pain in PsA subjects who have ostensibly good reduction of joint swelling under biological therapy has highlighted the potential impact of polyenthesitis in psoriatic disease. In daily practice, the formal demonstration of enthesitis is challenging for the following reasons: the relatively avascular nature of enthesis, often leading to the absence of overt clinical inflammatory signs; the frequent lack of elevation of inflammatory markers; and finally, the limitations of current imaging techniques to provide supportive evidence for inflammation in these areas. Consequently, enthesitis may present as widespread pain indistinguishable from FM or may emerge as the dominant feature after successful biological therapy for suppression of synovitis. The unmet needs in the differentiation between FM and enthesitis in psoriatic disease patients are highlighted and critically evaluated in this article.

2 Review Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. 2017

Khalil, Samar / Bardawil, Tara / Stephan, Carla / Darwiche, Nadine / Abbas, Ossama / Kibbi, Abdul Ghani / Nemer, Georges / Kurban, Mazen. ·a Department of Internal Medicine , American University of Beirut , Beirut , Lebanon. · b Department of Dermatology , American University of Beirut , Beirut , Lebanon. · c Department of Biochemistry and Molecular Genetics , American University of Beirut , Beirut , Lebanon. · d Department of Dermatology , Columbia University Medical Center , New York , NY , USA. ·J Dermatolog Treat · Pubmed #28318351.

ABSTRACT: Retinoids are a class of compounds derived from vitamin A or having structural and/or functional similarities with vitamin A. They are classified into three generations based on their molecular structures. Inside the body, retinoids bind to several classes of proteins including retinoid-binding proteins and retinoid nuclear receptors. This eventually leads to the activation of specific regulatory regions of DNA - called the retinoic acid response elements - involved in regulating cell growth, differentiation and apoptosis. Several clinical trials have studied the role of topical and systemic retinoids in disease, and research is still ongoing. Currently, retinoids are used in several fields of medicine. This paper aims to review the structure, mechanisms of action, and adverse effects of retinoids, as well as some of their current uses in Dermatology.

3 Review Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. 2017

Al Hammadi, Anwar / Al-Sheikh, Afaf / Ammoury, Alfred / Ghosn, Samer / Gisondi, Paolo / Hamadah, Issam / Kibbi, Abdul-Ghani / Shirazy, Khalid. ·a Department of Dermatology , Rashid Hospital , Dubai , UAE. · b Department of Dermatology , King Abdulaziz Medical City , Riyadh , Saudi Arabia. · c Department of Dermatology , St George Hospital University Medical Center , Beirut , Lebanon. · d Department of Dermatology , American University of Beirut Medical Center , Lebanon. · e Department of Dermatology , University Hospital of Verona , Italy. · f Department of Dermatology , King Faisal Hospital and Research Centre , Riyadh , Saudi Arabia. · g Pfizer Inc , Dubai , UAE. ·J Dermatolog Treat · Pubmed #27196814.

ABSTRACT: The incidence of psoriasis in Africa and the Middle East (AfME) is high as in other regions and represents a significant problem for both dermatologists and patients. Psoriasis co-morbidities such as obesity, cardiovascular disease and psoriatic arthritis (PsA) are also particularly common in these regions and may be under-recognized and under-treated. Despite this, regional guidelines to aid physicians on the appropriate use of biologic agents in their clinical practice are limited. A group of expert dermatologists from across the AfME region were surveyed to help establish best practice across the region, alongside supporting data from the literature. Although biologics have significantly improved patient outcomes since their introduction, the results of this survey identified several unmet needs, including the lack of consensus regarding their use in clinical practice. Discrepancy also exists among AfME physicians concerning the clinical relevance of immunogenicity to biologics, despite increasing data across inflammatory diseases. Significant treatment and management of challenges for psoriasis patients remain, and a move towards individualized, tailored care may help to address these issues. The development of specific local guidelines for the treatment of both psoriasis and PsA could also be a step towards understanding the distinct patient profiles in these regions.

4 Review Bariatric surgery and its effects on the skin and skin diseases. 2013

Halawi, Ali / Abiad, Firass / Abbas, Ossama. ·Department of Dermatology, American University of Beirut Medical Center, P.O.Box 11-0236, Riad El Solh, Beirut, 1107 2020, Lebanon. ·Obes Surg · Pubmed #23297168.

ABSTRACT: In light of the increasing prevalence of obesity worldwide, the popularity of bariatric surgery is on the rise. As with any other invasive procedure, these surgeries, especially with the obesity risk factor, carry the risk of direct cutaneous complications following the penetration and manipulation of tissues. In addition, bariatric surgery has an effect on skin structure and function. It also appears to be affiliated with several dermatoses. Some of these represent preexisting diseases the course of which is altered by the procedure, such as psoriasis. On the other hand, other skin disorders are triggered by the surgery itself. This article reviews and summarizes these cutaneous effects and complications.

5 Review Patented small molecules against psoriasis. 2009

Abdelnoor, Alexander M. ·American University of Beirut, Department of Microbiology & Immunology, Riad el-Solh, Beirut 1107 2020, Lebanon. aanoor@aub.edu.lb ·Expert Opin Ther Pat · Pubmed #19566378.

ABSTRACT: BACKGROUND: It is hypothesized that psoriasis is an autoimmune disease. The most recent therapeutic approach that proved to be more effective than earlier methods of treatment is the use of mAb/fusion proteins. Efforts nowadays are focused on investigating the antipsoriatic affect of small molecules that can be administered orally, some of which are capable of entering cells, and being selective in targeting intracellular pathways. OBJECTIVE: Preclinical patented small molecules that are recommended for the treatment of psoriasis are reviewed. Emphasis is placed on their mechanism of action. METHODS: http://ep.espacenet.com/ , Pubmed, Scopus and Google websites were the main sources used for the patented small molecule search. A number of patents were poorly described and difficulties were faced in trying to figure out the patentee(s) explanation. Moreover, most patents were recommended for the treatment of a number of autoimmune diseases and cancer, and not only for psoriasis. RESULTS/CONCLUSIONS: Small molecules that inhibit the activation of T lymphocytes, leukocyte trafficking, leukotriene activity/production and angiogenesis, and promote apoptosis have been patented. Small molecules that have been patented for the treatment of other autoimmune diseases and could be used for treating psoriasis are described. Moreover, other possible mechanistic approaches using small molecules are discussed.

6 Article Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis. 2018

Deyab, Gia / Hokstad, Ingrid / Aaseth, Jan / Småstuen, Milada Cvancarova / Whist, Jon Elling / Agewall, Stefan / Lyberg, Torstein / Tveiten, Dag / Hjeltnes, Gunnbjorg / Zibara, Kazem / Hollan, Ivana. ·Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway. Electronic address: Gia.Deyab@sykehuset-innlandet.no. · Lillehammer Hospital for Rheumatic Diseases, Norway. · Inland Norway University of Applied Sciences, Elverum, Norway; Department of Research, Innlandet Hospital Trust, Brumunddal, Norway. · Department of Public Health, Faculty of Nursing sciences, Oslo and Akershus University College, Oslo, Norway. · Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway; Department of Research, Innlandet Hospital Trust, Brumunddal, Norway. · University Hospital, Ullevål, Norway; Institute of Clinical Sciences, University of Oslo, Norway. · Department of Medical Biochemistry, Oslo University Hospital, Ullevål, Norway. · Lab1 AS, Sandvika, Norway. · Department of Medicine, Innlandet Hospital Trust, Lillehammer, Norway. · Department of Biology, Faculty of Sciences-l, Lebanese University, Beirut, Lebanon. · Lillehammer Hospital for Rheumatic Diseases, Norway; Department of Research, Innlandet Hospital Trust, Brumunddal, Norway; Harvard Medical School, Boston, USA; Brigham and Women's Hospital, Boston, USA. ·J Trace Elem Med Biol · Pubmed #29895378.

ABSTRACT: OBJECTIVES: The reason for increased cardiovascular risk in inflammatory arthritis (IA) is unclear. Interestingly, selenium-deficiency is suspected to contribute to the development of cardiovascular disease (CVD) in the general population. Although the reference range of serum selenium (s-selenium) is 50-120 μg/L, there are indications that levels up to 85 μg/L might not be sufficient for optimal cardioprotection. Our aim was to examine s-selenium levels in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), to evaluate the effect of anti-rheumatic treatment on s-selenium levels, and to assess relationships between s-selenium levels and clinical and laboratory parameters including markers of disease activity and CVD risk. METHODS: We examined 64 patients with RA, 40 with PsA and 26 with AS starting with methotrexate (MTX) monotherapy or anti-tumor necrosis factor therapy (anti-TNF) with or without methotrexate (anti-TNF ± MTX) due to active disease. S-selenium, inflammatory biomarkers, endothelial function (EF) and other variables were examined at baseline and after 6 weeks and 6 months of treatment. RESULTS: In the total IA group, s-selenium increased within 6 weeks of anti-rheumatic treatment, and thereafter the levels remained stable until the end of the 6 months follow-up period. There were no significant differences in s-selenium changes between the three diagnostic groups and between the two treatment regimens. Changes in s-selenium were negatively related to changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), but there were no significant relationships to any other of the examined risk parameters for CVD including EF. CONCLUSION: IA patients had s-selenium within the reference range, but below the level that might be necessary for optimal CVD protection. Anti-rheumatic treatment had a relatively rapid and sustained effect on s-selenium levels. The increase in s-selenium was related to reduction in inflammatory activity. In theory, anti-rheumatic drugs might improve s-selenium levels through inhibition of pro-inflammatory processes or through other mechanisms. Although we have not revealed any significant relationships between s-selenium and CVD risk parameters, the role of suboptimal s-selenium levels in pathogenesis of premature CVD in IA cannot be ruled out.

7 Article [Apparent worsening of psoriasis lesions revealing methotrexate overdosage]. 2018

Haber, R / Baroudjian, B / Battistella, M / Bagot, M / Petit, A. ·Service de dermatologie, St George Hospital University Medical Center, Beirut, Liban. Electronic address: rogerhaber@hotmail.com. · Service de dermatologie, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France. · Service de pathologie, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France. ·Ann Dermatol Venereol · Pubmed #28917574.

ABSTRACT: BACKGROUND: Methotrexate (MTX) is an antimetabolite drug used in the treatment of cancers and autoimmune diseases and frequently in dermatology for cutaneous and/or arthritic psoriasis. Toxicities due to MTX overdosage are mainly cutaneous, hepatic and hematologic. Herein, we report a case of MTX overdosage presenting as an erosive and an inflammatory flare of preexisting psoriatic plaques and with new palmar lesions. PATIENTS AND METHODS: A 51-year-old male with a 6-year history of plaque psoriasis resistant to topical corticosteroids was started for the first time on MTX 20mg weekly. One week later, he presented with fever, general weakness and mucocutaneous ulcerations. Physical examination revealed inflammatory, erythematous and partially erosive annular plaques strictly confined to preexisting psoriatic lesions, along with keratotic psoriatic palmar plaques. Further questioning indicated that the patient was taking MTX 20mg daily. Investigations revealed neutropenia (1040/mm DISCUSSION: Skin lesions due to acute MTX toxicity are rare, but they herald later-onset pancytopenia. Identification of these cutaneous lesions might enable earlier treatment initiation. The predilection of MTX toxicity for preexisting lesions or the de novo appearance of palmoplantar pustules should not lead to the erroneous diagnosis of psoriasis flare.

8 Article High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. 2016

Itani, Salam / Arabi, Asma / Harb, Dana / Hamzeh, Diana / Kibbi, Abdul-Ghani. ·Department of Dermatology, American University of Beirut, Beirut, Lebanon. · Division of Endocrinology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. ·Int J Dermatol · Pubmed #26748974.

ABSTRACT: BACKGROUND: Psoriasis is a chronic inflammatory disease that affects not only the skin but also other organs as well. Genetic factors play an important role in individual predisposition. Lately, a positive association has been confirmed between psoriasis and metabolic syndrome (MBS), in western as well as in Middle Eastern countries. AIM: Assess the prevalence of MBS in Lebanese patients with psoriasis and the differential effect according to types and disease severity. METHODS: This was a case-control study including 150 psoriasis patients and 150 age- and gender-matched controls admitted to the dermatology clinics at the American University of Beirut-Medical Center, a tertiary care center in Beirut. Psoriasis severity was assessed by the Psoriasis Area Severity Index (PASI). Blood samples were collected from fasting subjects and tested for glucose, HDL cholesterol, triglycerides, and C-reactive protein (CRP). Multivariate binary logistic regression models were built to assess the relationship between MBS and psoriasis, after adjustment for smoking as a possible confounding variable. RESULTS: Patients with psoriasis were two times more likely to have MBS as compared to controls (35.3% vs 18.0%, P < 0.001) with an odds ratio (OR) of 2.4. All components of MBS were more prevalent in psoriasis patients than in controls. PASI score was greater in patients with MBS than those without MBS (10.5 ± 11.5 vs. 7.0 ± 8.1, P = 0.05). MBS prevalence tended to be higher in the inverse type than in others (52.2% versus 32.3%; P = 0.06) and in patients with nail pitting versus those without (45.3% vs. 28.2%; P = 0.03). CONCLUSIONS: This was the first study to assess the prevalence of MBS in Lebanese subjects with psoriasis and, to our knowledge, the first study that showed a higher likelihood of MBS in patients with inverse psoriasis and with nail pitting.

9 Article Acrodermatitis continua of Hallopeau is a clinical phenotype of DITRA: evidence that it is a variant of pustular psoriasis. 2013

Abbas, Ossama / Itani, Salam / Ghosn, Samer / Kibbi, Abdul Ghani / Fidawi, Georges / Farooq, Muhammad / Shimomura, Yutaka / Kurban, Mazen. ·Department of Dermatology, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon. ·Dermatology · Pubmed #23428889.

ABSTRACT: Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic, sterile, pustular eruption that predominantly affects the fingertips with nail involvement. While some consider ACH a distinct entity, many believe it to be a variant of pustular psoriasis, especially as cases of ACH progressing to generalized pustular psoriasis (GPP) have been reported. Recently, recessively inherited mutations in the IL36RN gene, which encodes interleukin-36 receptor antagonist (IL-36Ra), have been demonstrated to be the cause of familial GPP, a condition termed DITRA (deficiency of IL-36Ra). Here, we identified a homozygous missense mutation c.338C>T (p.Ser113Leu) in the IL36RN gene in a male patient with ACH, as well as in his sister who had a history of GPP.

10 Article Dermacase: Can you identify this condition? Tumid lupus erythematosus. 2012

Abdullah, Lina / Abbas, Ossama. ·Department of Nursing at the American University of Beirut in Lebanon. ·Can Fam Physician · Pubmed #22798463.

ABSTRACT: -- No abstract --

11 Article [Oral lesions in psoriasis]. 2010

Tomb, R / Hajj, H / Nehme, E. ·Département de dermatologie, université Saint-Joseph, Beyrouth, Liban. rtomb@usj.edu.lb ·Ann Dermatol Venereol · Pubmed #21074652.

ABSTRACT: BACKGROUND: The literature contains little information about the incidence or prevalence of oral signs in psoriasis. The pustular forms are the most commonly incriminated, with geographic tongue being the most frequently cited oral sign. The aim of our study was to determine the various types of oral signs seen in a large population of psoriasis patients. PATIENTS AND METHODS: Four hundred psoriasis patients were recruited consecutively and a detailed oral examination performed by two clinicians. Similar examinations were performed over the same period in 1000 nonpsoriasis subjects comprising a control group in order to assess the incidence of the same oral signs in the general population. RESULTS: Comparing the two groups, fissured tongue was seen in 33.2% of psoriasis patients versus 9.9% of control subjects (P<0.0001). There was thus a highly significant (P<0.0001) correlation between geographic tongue and psoriasis (7.7% of psoriasis patients versus 1% of controls). In addition, a strong correlation was seen between the presence of pustular psoriasis and fissured tongue (83.3% of patients with pustular psoriasis versus only 30% of patients with other forms of psoriasis). DISCUSSION: Our study shows a strong correlation between psoriasis and fissured and geographic tongue, although these features are not pathognomonic for the disease. As regards geographic tongue, our results are consistent with the data in the literature. However, the prevalence of fissured tongue was considerably higher among our patients than in series published to date. These two types of sign involving the tongue, and which can occur in all forms of psoriasis, appear to be particularly strongly associated with pustular psoriasis. Patients are generally unaware of this sign and rarely complain of it.

12 Article Superficial morphea: 20-year follow up in a patient with concomitant psoriasis vulgaris. 2009

Saleh, Zenus / Arayssi, Thuraya / Saleh, Zeinab / Ghosn, Samer. ·Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon. ·J Cutan Pathol · Pubmed #19602063.

ABSTRACT: Superficial morphea, a newly described variant of morphea, manifests clinically with hypopigmented or hyperpigmented patches that lack induration. The lesions show on biopsy dermal sclerosis in the superficial to mid-reticular dermis. So far, all cases reported in the literature were skin limited. In this report, we describe a 24-year-old female patient who developed at the age of 4 years plaques characteristic, both clinically and histologically, of superficial morphea. The patient developed later on psoriasis vulgaris. Although the association of scleroderma and psoriasis is rarely reported in the literature, most reports describe a progressive systemic course of scleroderma whenever the two diseases co-exist. This is the first report to describe superficial morphea in association with psoriasis and to provide a 20-year follow-up period during which the superficial morphea remained relatively stable with no evidence of systemic involvement.

13 Article Streptococcus sp. and Staphylococcus aureus isolates from patients with psoriasis possess genes that code for toxins (superantigens): clinical and therapeutic implications. 2008

El Ferezli, Jessica / Jenbazian, Lori / Rubeiz, Nelly / Kibbi, Abdul-Ghani / Zaynoun, Shukrallah / Abdelnoor, Alexander M. ·Department of Microbiology and Immunology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. ·Immunopharmacol Immunotoxicol · Pubmed #18569077.

ABSTRACT: Superantigens are powerful T lymphocyte-stimulating agents that are believed to contribute to the pathogenesis of certain diseases such as psoriasis. Toxins produced by Streptococcus pyogenes and Staphylococcus aureus are superantigens. The aim of this study was to detect genes that code for superantigens in Streptococcus and Staphylococcus aureus isolates from psoriatic patients. Primers to amplify streptococcal pyrogenic exotoxin A, B, and C and streptolysin O genes and staphylococcal enterotoxin A, B, C, and D genes were used. Streptococcal exotoxin B was detected in five streptococcal isolates. Staphyloccocus aureus enterotoxin A and/or C genes were detected in nine S. aureus isolates. Isolates from 13 of 22 patients possesed gene(s) that code for toxin(s) (superantigens). These results might support the role of superantigens in the exacerbation of psoriasis.